Loading
companiesCompany
Akeso
Chinese biotech whose ivonescimab beat Keytruda head-to-head, and developer of the Nectin-4×TROP2 ADC.
Overview
Akeso, based in Zhongshan and listed in Hong Kong as 9926.HK, is the Chinese biotechnology company whose ivonescimab beat pembrolizumab head to head in the HARMONi-2 trial, and the developer of the Nectin-4 by TROP2 bispecific ADC AK146D1. Its portfolio includes ivonescimab, a PD-1 by VEGF bispecific, cadonilimab, a PD-1 by CTLA-4 bispecific proved in COMPASSION-16 in cervical cancer, and penpulimab, with Michelle Xia, Caicun Zhou and Wenfeng Fang among the people linked. OnCo connects it to lung, cervical and nasopharyngeal cancer, to HARMONi-A, to the bispecific ADC technology and to the NMPA, and to bottlenecks on regulatory divergence and trials that do not represent the people who get cancer. Whether the HARMONi-2 result holds in global trials run by its partner Summit is the open question. Ivonescimab has its own page.
Headquarters
Zhongshan, CN
Scorecard
All companies#38of 1244 companies, score 81
- approved products +18
- phase 3 +3
- phase 1/2 +2
- targets +14
- modalities +6
- regions +2
- 24-month regulatory events +6
- registry trials +30
3 approved, 1 in phase 3, 2 earlier, 7 targets, 356 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-12-06 | Akeso to Summit Therapeutics Ivonescimab (AK112, SMT112), PD-1 x VEGF bispecific | Licence | $500m | up to $5.0bn | source |
Catalysts
What is due next- 2027expectedHARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy, first-line NSCLC
The first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population. Timing is our estimate from the registry record; the sponsor has not given a date. Source
Type
Biotech · 9926.HK
Stage
Public
Website
ApprovedBispecific antibody (PD-1×VEGF)
A Chinese bispecific that beat Keytruda head-to-head on progression-free survival in lung cancer, the first drug ever to do so.
Phase 1Bispecific ADC
AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.
Phase 3monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)
AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Phase 2monoclonal antibody
AK119 is an experimental monoclonal antibody from Akeso in phase 2 trials for colorectal cancer, aimed at CD73 / adenosine axis.
ApprovedBispecific antibody (PD-1×CTLA-4)
Cadonilimab · Kaitanni
A Chinese two-armed antibody that blocks PD-1 and CTLA-4 together, approved in China for cervical cancer and extending survival even in PD-L1-negative tumours.
ApprovedAnti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)
Penpulimab · Penpulimab-kcqx
Penpulimab is a Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab.
Caicun Zhou
Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027)
Lung cancerEGFR inhibitorsImmunotherapy
Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients.
Michelle Xia (Xia Yu)
Founder, Chairwoman and CEO, Akeso
Bispecific antibodiesAntibody discoveryBiotech leadership
Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.
Wenfeng Fang
Professor of Medical Oncology, Sun Yat-sen University Cancer Center
Lung cancerImmunotherapyNasopharyngeal carcinoma
Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.
Similar pages
- TechnologyBispecific antibodies
Shares A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma, A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection, A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor, An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer.
cancers
fronts
technologies
drugs
Phase 3monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)
Phase 2monoclonal antibody
Phase 1Bispecific ADC
ApprovedBispecific antibody (PD-1×CTLA-4)
Cadonilimab · Kaitanni
ApprovedBispecific antibody (PD-1×VEGF)
ApprovedAnti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)
Penpulimab · Penpulimab-kcqx
institutions
trials
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsA Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal CancerA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerA Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal CancerA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic HepatA Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent ChemorA Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerA Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic CancerA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerA Study of Ivonescimab in First-Line ES-SCLCA Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaA Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaAK104 for Recurrent or Metastatic Vulvar CancerAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerAK112 and Chemotherapy in First-line Metastatic Colorectal CancerAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase InhibitorAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerAK129 Combination Therapy for Advanced Solid TumorsAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerCombination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerCOMPASSION-16 / AK104-303ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)HARMONi-2HARMONi-AIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerNeoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerSCRT Followed by AK112 in pMMR/MSS Mid-low Rectal CancerStudy of AK119 Combined With AK112 in Patients With Advanced Solid Tumors